Sa1052 Triple Therapy Under Real Life Conditions: Telaprevir (TVR) in Combination With Peginterferon-Alfa-2A Plus Ribavirin (P/R) in NaïVE Patients Infected With Chronic Hepatitis C, Genotype 1. The PAN Study

the first 12weeks 11.9% and 5.9% of the patients required dose modifications of ribavirin and peginterferon alfa-2a, respectively and 2 (3.0%) and 17 (25.4%) patients had haemoglobin ,8.5 g/dL and ≥8.5 but ,10 g/dL respectively. Adverse events reported in at least 15% of patients included fatigue (52.9%), nausea (26.5%), headache (25.0%), skin disorder (23.5%), dysgeusia (19.1%), pruritus (19.1%), myalgia (17.6%), anaemia (16.2%) andarthralgia (16.2%). Conclusion: Real world experience with BOC plus peginterferon alfa2a/ribavirin in Germany show similar virological outcomes and side effects to the phase 3 trials. Week 8 HCV RNA values essential to determine suitability for reduced treatment duration were not collected in a significant proportion of patients.